Search clinical trials for: Enzyme Activators

Total 48183 results

Eli Lilly and Company

Completed

A Study of LY2608204 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Singapore, United States
Eli Lilly and Company

Completed

A Study to Compare Two Forms of LY2608204 in Healthy People

Healthy Volunteers

Singapore
Northwestern University

Suspended

Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19

Covid19

United States
University Hospital, Tours

Completed

French National Cohort of Children With Port Wine Stain (CONAPE)

Port Wine Stain | Parkes Weber Syndrome | Klippel Trenaunay Syndrome

France
University of Colorado, Denver
Bayer

Recruiting

Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty

Chronic Thromboembolic Disease (CTED) | Exercise Intolerance Post PEA Surgery

United States
Mark Gladwin

Completed

A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases

Sickle Cell Disease

United States
Medical University of Vienna

Completed

Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (DYNAMIC)

Hypertension, Pulmonary | Heart Failure With Normal Ejection Fraction

Austria
University of Cincinnati

Unknown

Riociguat for Sarcoidosis Associated Pulmonary Hypertension (RioSAPH)

Sarcoidosis

United States
Al-Azhar University

Enrolling by invitation

Ethically Accepted With Code 851/2971 A Comparison of Class Ⅱ Malocclusion Treatment Using Van Beek-headgear Activator Versus Andresen Activator

Class II Growth Modification

Egypt
Dinesh Khanna, MD, MS
Bayer

Completed

Riociguat in Scleroderma Associated Digital Ulcers (RESCUE)

Scleroderma | Digital Ulcers

United States
Spinal Missions, Inc., LLC

Completed

Measure the Effects of Specific Thoracic Chiropractic Adjustments on Blood Pressure and Pulse Rate

Hypertension
Medical University of Graz

Completed

Efficacy of Instrumental Chiropractic Treatment Using Activator Methods for Pain and Dysfunction in Juvenile Athletes

Pain in Leg, Unspecified | Knee Sprain

Austria
Bayer

Completed

Relative Bioavailability and Food Effect Study

Pharmacology, Clinical

Germany
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat

Sickle Cell Disease | Hemolytic Anemia

United States
Bayer

Completed

Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH) (JPMS-PAH)

Hypertension, Pulmonary

Japan
Bayer

Completed

Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor (RESPITE)

Hypertension, Pulmonary

Belgium, United States, Switzerland, Canada, France, Germany, Italy, United Kingdom, Czechia
Bayer

Completed

A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice (CAPTURE)

Hypertension, Pulmonary

Japan, Germany, Sweden, Colombia, Turkey, Belgium, Canada
Université du Québec a Montréal

Completed

Heart Rate Variability Modulation Following a Manipulation in Pain Free Patients Versus Patients in Pain

Low Back Pain

Canada
Bayer

Completed

BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension (PATENT-2)

Hypertension, Pulmonary

Belgium, France, China, Turkey, Portugal, Taiwan, Japan, Singapore, United States, Argentina, Switzerland, Mexico, Austria, Thailand, Canada, Denmark, Germany, Russian Federation, Australia, Italy, Korea, Republic of, Sweden, Poland, United... and more
Bayer

Completed

EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension (EXPERT)

Hypertension, Pulmonary

Turkey, Austria, Czechia, Russian Federation, Slovakia, Switzerland, Italy, Germany, United Kingdom, France, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Taiwan, Denmark, Sweden, Argentina, Portugal, Saudi Arabia, Austral... and more
Richard Moon

Completed

Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude

Altitude Sickness | Hypertension, Pulmonary

United States
Bayer

Terminated

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction (DILATE)

Hypertension, Pulmonary | Ventricular Dysfunction, Left

Austria, Germany, Czech Republic
Stimit AG

Completed

"Electromagnetical Stimulation of Phrenic Nerve to Generate Contraction of the Diaphragm"

Healthy Subjects | Elective Surgical Procedure

Switzerland
Stimit AG

Recruiting

STIMIT Activator 1 IDE Pivotal Study

Diaphragm Issues

United States
National Hospital Organization Okayama Medical...
Bayer Yakuhin, Ltd.

Recruiting

THERAPY-HYBRID-BPA Trial

Hypertension, Pulmonary

Japan
Bayer
Merck Sharp & Dohme LLC

Active, not recruiting

Riociguat in Children With Pulmonary Arterial Hypertension (PAH) (PATENT-CHILD)

Hypertension, Pulmonary

Germany, Turkey, Japan, Italy, Mexico, Poland, Hungary, Colombia, Taiwan
Bayer
Xcenda, LLC

Active, not recruiting

A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH) (ROAR)

Pulmonary Arterial Hypertension

United States, Puerto Rico
Bayer

Completed

Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH ) (JPMS-CTEPH)

Hypertension, Pulmonary

Japan
Bayer

Completed

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) (PATENT-1)

Pulmonary Hypertension

Belgium, France, Spain, China, United States, Turkey, New Zealand, Portugal, Taiwan, Japan, Australia, Singapore, Argentina, Sweden, Switzerland, Mexico, Austria, Thailand, Canada, Denmark, Germany, Israel, Russian Federation, Italy, Korea... and more
Bayer

Completed

Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight

Clinical Pharmacology

Germany
Yabao Pharmaceutical Group

Completed

Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Hyperglycaemia (Diabetic)

China
Bayer

Completed

Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)

Hypertension, Pulmonary

United States, Puerto Rico
Bayer

Completed

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. (CHEST-1)

Pulmonary Hypertension

Belgium, France, Spain, Turkey, Portugal, Taiwan, Japan, United States, Switzerland, Korea, Republic of, Austria, Canada, China, Denmark, Germany, Russian Federation, Mexico, Argentina, Netherlands, Italy, Poland, United Kingdom, Au... and more
Bayer

Completed

Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

Scleroderma, Systemic

Netherlands, Belgium, United States, Australia, Hungary, United Kingdom, Canada, Germany, Switzerland, France, Italy, Japan, New Zealand, Turkey, Czechia
Bayer

Completed

Relative Bioavailability Study

Healthy Volunteers

Germany
Bayer

Completed

An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension

Hypertension, Pulmonary

Germany
Hoffmann-La Roche

Completed

A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.

Diabetes Mellitus Type 2

United States, Slovakia
Heidelberg University
Merck Sharp & Dohme LLC

Recruiting

Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH (RIVERII)

Chronic Thromboembolic Pulmonary Hypertension | Primary Pulmonary Arterial Hypertension

Germany
Bayer

Recruiting

A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension. (RIALTO)

Hypertension, Pulmonary

France, Italy, Korea, Republic of, Poland, Thailand
Bayer

Active, not recruiting

Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

Hypertension, Pulmonary

Germany
Agios Pharmaceuticals, Inc.

Active, not recruiting

Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

Pyruvate Kinase Deficiency

United States, Spain, Japan, Canada, United Kingdom, Korea, Republic of, Ireland, Thailand, Italy, Turkey, Denmark, Brazil, France, Germany, Netherlands, Switzerland
Bayer

Completed

BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension (CHEST-2)

Pulmonary Hypertension

Belgium, France, Spain, Turkey, Portugal, Taiwan, Japan, United States, Switzerland, Korea, Republic of, Austria, Canada, China, Denmark, Germany, Mexico, Russian Federation, Argentina, Italy, Poland, Australia, Brazil, Czechia, United... and more
Bayer

Active, not recruiting

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (LEPHT)

Hypertension, Pulmonary | Ventricular Dysfunction, Left

Belgium, France, China, Spain, Japan, United States, Singapore, Canada, Switzerland, Austria, Denmark, Germany, Italy, Australia, Czechia, Netherlands, Poland, United Kingdom
Agios Pharmaceuticals, Inc.

Enrolling by invitation

A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study

Anemia, Hemolytic | Pyruvate Kinase Deficiency

Japan
Humanis Saglık Anonim Sirketi

Completed

Bioequivalence Study of Riociguat 2.5 mg Film Coated Tablets and Adempas (Riociguat) 2.5 mg Film Coated Tablets

Pulmonary Arterial Hypertension

India
Bausch Health Americas, Inc.
Syneos Health

Completed

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

Chronic Idiopathic Constipation

United States, Canada
Yabao Pharmaceutical Group

Completed

The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride

Healthy Volunteers | Hyperglycaemia (Diabetic)

China
Johnson & Johnson Surgical Vision, Inc.

Completed

Evaluation of the LipiFlow System With a New Activator

Meibomian Gland Dysfunction

United States
Institut Franco Europeen de Chiropratique

Unknown

the Hypoalgesic Effect of Spinal Manual Therapy

Back Pain

Australia
RenJi Hospital

Completed

Pressure Pain Thresholds and Basal Electromyographic Activities Following Spinal Mechanical Manipulation

Pain

China

Search clinical trials for: Enzyme Activators

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations